Skip to main content
Back to feed
MarketsSingle-sourceLowDeveloping
2.1

Aschelia Pharma CFO departs following equity valuation decline

Aschelia Pharma CFO Anton Hansson is stepping down amid a significant share price collapse and ongoing corporate restructuring. The company is implementing cost-saving measures while attempting to maintain development momentum for its lead drug candidate, Orviglance.

Dagens Industri3 days agoSECredibility 27%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#biotech#c-suite#restructuring#equity

Entities

country
Source

Related signals

8 found